Insider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells 44,904 Shares of Stock

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Gary Ingenito sold 44,904 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $21.96 on Friday. The stock has a market capitalization of $2.67 billion, a PE ratio of 18.61, a P/E/G ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a 1-year low of $14.47 and a 1-year high of $24.64. The business has a 50-day moving average of $22.27 and a 200 day moving average of $21.49.

Analysts Set New Price Targets

A number of equities analysts have weighed in on CPRX shares. Truist Financial upped their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Robert W. Baird upped their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Bank of America reiterated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of “Buy” and an average price target of $32.50.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC purchased a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at about $27,000. Park Square Financial Group LLC purchased a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at about $29,000. Farther Finance Advisors LLC raised its position in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,495 shares during the last quarter. Larson Financial Group LLC raised its position in Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 2,994 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in Catalyst Pharmaceuticals during the 4th quarter valued at approximately $65,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.